Torrent Pharmaceuticals Ltd Stock Price Today (NSE: TORNTPHARM)
Fundamental Score
Torrent Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Torrent Pharmaceuticals Ltd share price today is ₹4229.60, up +0.00% on NSE/BSE as of 20 February 2026. Torrent Pharmaceuticals Ltd (TORNTPHARM) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.26L (Cr). The 52-week high for TORNTPHARM share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 58.36x, TORNTPHARM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 26.52% and a debt-to-equity ratio of 0.33.
Torrent Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Torrent Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Torrent Pharmaceuticals Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, while offering essential products, often presents valuation challenges for conservative investors. Regulatory hurdles, patent cliffs, and evolving therapeutic landscapes demand a cautious approach. This analysis examines the current standing of the Torrent Pharmaceuticals share price (₹3939.0) through a value investing lens, emphasizing capital safety and long-term sustainability. Our analysis is part of a comprehensive, 80-parameter fundamental audit of Torrent Pharmaceuticals Ltd, verified by Sweta Mishra.
A key metric for value investors is the Price-to-Earnings (PE) ratio. Torrent Pharmaceuticals Ltd's current PE of 58.36 appears relatively high when compared to the broader market. This suggests that the market has significant expectations for future earnings growth. It will be important to understand if this premium is justified.
One area where Torrent Pharmaceuticals Ltd demonstrates strength is its Return on Capital Employed (ROCE) of 27.05%. This robust ROCE indicates that the company is efficiently generating profits from its invested capital. This level of profitability can be indicative of a competitive advantage, a "moat" that helps protect the company's market share and profitability from competitors. Sustained high ROCE can translate to long-term shareholder value creation.
Benchmarking against peers provides further context. While we cannot comment on specific qualitative aspects, we can observe that the management quality of a company is a significant factor. While objective comparisons with
Mankind Pharma Ltd's management are beyond the scope of this quantitative analysis, observing the capital allocation decisions and strategic direction of both companies over time can be informative.In conclusion, while the current Torrent Pharmaceuticals share price reflects optimistic market expectations, the company's strong ROCE offers a degree of comfort. A conservative value investor should diligently assess the sustainability of this profitability, and deeply consider management's ability to protect the company's competitive position and allocate capital effectively in the future before making any investment decisions. The high PE ratio needs to be justified by future growth.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Torrent Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TORNTPHARM across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (26.52%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.05%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (30.68%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (32.49%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Interest Coverage (14.47x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹10189.41 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.31%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 25.09%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Premium Valuation Risk (P/E: 58.36x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Torrent Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Torrent Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About TORNTPHARM (Torrent Pharmaceuticals Ltd)
Torrent Pharmaceuticals Ltd (TORNTPHARM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹1.26L (Cr). Torrent Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 26.52% and a ROCE of 27.05%. The debt-to-equity ratio stands at 0.33, reflecting the company's capital structure. Investors tracking TORNTPHARM share price can monitor key metrics including P/E ratio, promoter holding of 68.31%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
TORNTPHARM Share Price: Frequently Asked Questions
What is the current share price of Torrent Pharmaceuticals Ltd (TORNTPHARM)?
As of 20 Feb 2026, 06:25 am IST, Torrent Pharmaceuticals Ltd share price is ₹4229.60. The TORNTPHARM stock has a market capitalisation of ₹1.26L (Cr) on NSE/BSE.
Is TORNTPHARM share price Overvalued or Undervalued?
TORNTPHARM share price is currently trading at a P/E ratio of 58.36x, compared to the industry average of 31.77x. Based on this relative valuation, the Torrent Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of TORNTPHARM share price?
The 52-week high of TORNTPHARM share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Torrent Pharmaceuticals Ltd share price?
Key factors influencing TORNTPHARM share price include quarterly earnings growth (Sales Growth: 14.30%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Torrent Pharmaceuticals Ltd a good stock for long-term investment?
Torrent Pharmaceuticals Ltd shows a 5-year Profit Growth of 13.84% and an ROE of 26.52%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.33 before investing in TORNTPHARM shares.
How does Torrent Pharmaceuticals Ltd compare with its industry peers?
Torrent Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare TORNTPHARM share price P/E of 58.36x and ROE of 26.52% against the industry averages to determine competitive standing.
What is the P/E ratio of TORNTPHARM and what does it mean?
TORNTPHARM share price has a P/E ratio of 58.36x compared to the industry average of 31.77x. Investors pay ₹58 for every ₹1 of annual earnings.
How is TORNTPHARM performing according to Bull Run's analysis?
TORNTPHARM has a Bull Run fundamental score of 65.3/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does TORNTPHARM belong to?
TORNTPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Torrent Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for TORNTPHARM?
TORNTPHARM has an ROE of 26.52%, which indicates excellent management efficiency. ROE measures how efficiently Torrent Pharmaceuticals Ltd generates profits from shareholders capital.
How is TORNTPHARM debt-to-equity ratio and what does it indicate?
TORNTPHARM has a debt-to-equity ratio of 0.33, which indicates moderate leverage that should be monitored.
What is TORNTPHARM dividend yield and is it a good dividend stock?
TORNTPHARM offers a dividend yield of 0.86%, meaning you receive ₹0.86 annual dividend for every ₹100 invested in Torrent Pharmaceuticals Ltd shares.
How has TORNTPHARM share price grown over the past 5 years?
TORNTPHARM has achieved 5-year growth rates of: Sales Growth 7.72%, Profit Growth 13.84%, and EPS Growth 13.84%.
What is the promoter holding in TORNTPHARM and why does it matter?
Promoters hold 68.31% of TORNTPHARM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Torrent Pharmaceuticals Ltd.
What is TORNTPHARM market capitalisation category?
TORNTPHARM has a market capitalisation of ₹126431 crores, placing it in the Large-cap category.
How volatile is TORNTPHARM stock?
TORNTPHARM has a beta of N/A. A beta > 1 suggests the Torrent Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is TORNTPHARM operating profit margin trend?
TORNTPHARM has a 5-year average Operating Profit Margin (OPM) of 30.68%, indicating the company's operational efficiency.
How is TORNTPHARM quarterly performance?
Recent quarterly performance shows Torrent Pharmaceuticals Ltd YoY Sales Growth of 14.30% and YoY Profit Growth of 32.49%.
What is the institutional holding pattern in TORNTPHARM?
TORNTPHARM has FII holding of 15.92% and DII holding of 9.17%. Significant institutional holding often suggests professional confidence in the Torrent Pharmaceuticals Ltd stock.